Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch-Maintenance Gemcitabine in Malignant Pleural Mesothelioma
NCT05660616Phase 2Completed
- Sponsor
- Ain Shams University
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in malignant pleural mesothelioma (MPM) (2 arms), sponsored by Ain Shams University. Primary endpoint: progression free survival at 2 years. Started Apr 2023; status: completed.
02
Drugs
gemcitabine
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT05660616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660616.